ArticleJAMA oncology2018

Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.

Brian H Kushner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.